GSK/Genmab submit MAA in EU for Arzerra in CLL
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and partner Genmab have submitted a market authorization application in Europe for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy.